
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : $137.2 million
Deal Type : Licensing Agreement
Details : Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $0.4 million
May 11, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : $137.2 million
Deal Type : Licensing Agreement
